Guardant360 CDx Receives European Approval as Companion Diagnostic for Camizestrant in ESR1-Mutated Advanced Breast Cancer
Guardant360 CDx received EU approval as a companion diagnostic for AstraZeneca's camizestrant in ER-positive, HER2-negative advanced breast cancer. The blood test detects ESR1 mutations, aiding treatment decisions. The approval follows similar nods in the US and Japan, based on the SERENA-6 trial showing improved progression-free survival with camizestrant.
How this was made
The 30-second read
Why it matters
EU CE marking for Guardant360 CDx expands the approved diagnostic geography and strengthens the drug-diagnostic linkage for ESR1-mutated ER+/HER2- advanced breast cancer.
Market read
A company-specific EU regulatory approval for the companion diagnostic can drive incremental demand expectations for Guardant Health’s assay platform.
What to watch
The article does not quantify EU sales, reimbursement status, or utilization rates for Guardant360 CDx, so the market may over- or under-react without those datapoints.
Background
The companion diagnostic is designed to detect ESR1 mutations in blood (ctDNA) to enable a ctDNA-triggered switch to camizestrant in patients without radiographic progression.
Ticker impact
Guardant360 CDx received CE marking in the EU as a companion diagnostic for camizestrant to identify ESR1-mutated ER+/HER2- advanced breast cancer patients.
Likely positive bias as the market prices in broader EU adoption and improved reimbursement/label access for the assay.
The article is a direct, company-specific regulatory approval for Guardant360 CDx (CE marking) tied to a specific oncology drug indication, which can support incremental sales and partner validation.
Market effects
Reinforces the ESR1 ctDNA companion-diagnostic model in HR+/HER2- breast cancer, potentially supporting sentiment for liquid biopsy and precision oncology diagnostics.
Improves EU commercialization prospects for the Guardant360 CDx-camizestrant pairing versus prior US/Japan-only positioning.
Adds another major geography (EU) to the drug-diagnostic co-development footprint, supporting global adoption expectations for ctDNA-guided treatment switching.
Counterpoint
EU CE marking does not guarantee rapid uptake; payer coverage, clinician adoption, and test ordering workflows may limit near-term revenue impact.
Key entities
- diagnostic assayGuardant360 CDx
Blood-based ctDNA test detecting ESR1 mutations, approved in the EU as a companion diagnostic for camizestrant.
- oncology drugcamizestrant (Etcamah)
ER antagonist used with a CDK4/6 inhibitor; EU approval is tied to ESR1 mutation status.
- phase 3 trialSERENA-6
Trial supporting camizestrant’s indication, using ctDNA to trigger switching strategy.
